Recasts paragraph 1 to add valuation
June 16 (Reuters) - Cancer diagnostic firm Caris Life Sciences said on Monday it was targeting a valuation of $5.67 billion in its U.S. initial public offering, after raising its proposed price range.
The Irving, Texas-based company is marketing the IPO at a price range between $19 and $20 apiece, according to a regulatory filing. It is seeking up to $470.6 million.
BofA Securities, J.P. Morgan, Goldman Sachs and Citigroup are the lead underwriters.
Caris will start trading on the Nasdaq on Wednesday under the symbol 'CAI'.
(Reporting by Arasu Kannagi Basil and Pritam Biswas in Bengaluru; Editing by Shreya Biswas)
((ArasuKannagi.Basil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。